多巴丝肼联合多巴胺受体激动剂治疗帕金森病的临床研究  

The clinical study of levodopaand benserazide hydrochlo-ride combining with dopamine receptor agonist in the treatment of Parkinson disease

作　　者：吴学良[1] 陈汉杰[1] 陈勋[1] 

机构地区：[1]广东省普宁市人民医院,广东普宁515300

出　　处：《中国当代医药》2013年第19期62-63,共2页China Modern Medicine

摘　　要：目的探讨多巴丝肼联合多巴胺受体激动剂治疗帕金森病的临床疗效。方法选择本院2011年3月～2012年5月收治的帕金森病患者38例,分为对照组和治疗组,对照组采用多巴丝肼进行治疗,治疗组在对照组的基础上采用多巴胺受体激动剂进行治疗,治疗4个月后,观察两组患者的临床效果。结果两组治疗4个月后,治疗组的Webster评分为(8.11±1.78)分,明显低于对照组的(11.33±3.98)分,两组相比差异有统计学意义(P<0.05);治疗组的UPDRS评分为(10.58±6.22)分,亦明显低于对照组的(23.67±7.78)分,两组比较差异有统计学意义(P<0.05)。结论多巴丝肼联合多巴胺受体激动剂可以有效地改善帕金森患者的自主活动能力,值得在临床上推广。Objective To explore the clinical curative effects of levodopaand benserazide hydrochlo-ride combining with dopamine receptor agonist in the treatment of Parkinson disease.Methods Thirty eight patients with Parkinson disease accepted treatment in our hospital from March 2011 to May 2012 were divided into control group and treat ment group.In the control group,patients were treated by levodopaand benserazide hydrochlo-ride,while in the treat ment group,on the basis of the control group,dopamine receptor agonist was added.After 4-month treatment,the clinical effects in both groups were observed.Results After 4 months,the Webster score in the treatment group was（8.11 ±1.78）,greatly lower than that in the control group（11.33±3.98）,which displayed statistically significant difference（P0.05）.In addition,the score of unified Parkinson disease rating scale（UPDRS） in the treatment group was（10.58 ±6.22）,remarkably lower than that in the control group（23.67 ±7.78）,with statistical difference（P 0.05）.Conclusion The levodopaand benserazide hydrochlo-ride combining with dopamine receptor agonist can effectively improve locomotor ac tivities in patients with Parkinson disease,which is worthy of extension in clinic.

关 键 词：多巴丝肼 多巴胺受体激动剂 帕金森病 临床研究 

分 类 号：R971[医药卫生—药品]